ArticleMedical oncology (Northwood, London, England)2026
Thymoquinone decreases cell proliferation and immune evasion of breast cancer cells by reducing CD55 and CD114 levels.
Article in Medical oncology (Northwood, London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Controlling the proliferation and immune evasion of cancer cells can lead to effective strategies for cancer treatment. Thymoquinone, a bioactive compound derived from Nigella sativa exhibits a potent anti-tumor activity. It can be used as a therapeutic approach because it stabilizes the G-quadruplex structure in the promoter regions of oncogenes. This study aims to investigate the effects of thymoquinone on CD55, an inhibitor of the complement system, and CD114, which is involved in cancer cell proliferation. Real-time PCR and Western blot were conducted to verify the expression of CD55 and CD114 in patients' tumor samples, HMEC cells, MCF-7 cells, and MCF7-cancer stem cells (MCF7-CSCs). MCF-7 cells were treated with thymoquinone, and their biological behavior was evaluated using proliferation, migration, and wound-healing assays. The result indicated that CD55 and CD114 were induced among the patient's samples. The same result is followed by MCF-7 cells and MCF7-CSCs. Treatment of MCF-7 and MCF7-CSCs with thymoquinone effectively downregulated CD55 and CD114 and suppressed the stemness markers Sox2 and Nanog. Promoter analysis revealed the putative G-quadruplex sequences in the CD55 and CD114 genes. Thymoquinone binds to them at the CD55 and CD114 promoters, thereby limiting mRNA expression. Additionally, the inhibition of their expression reduced cell movement and growth, as verified by biological assays. In summary, treating breast cancer cells with thymoquinone could stabilize the G-quadruplex structure on the promoter regions of CD55 and CD114 and hinder their mRNA expression. Therefore, restoring immune recognition and inhibition of proliferation. Hence, thymoquinone could be a potent target for breast cancer therapeutics.
Indexed as
Identifiers
41893940What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.